Literature DB >> 23979200

Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients.

A Choughule1, V Noronha, A Joshi, S Desai, N Jambhekar, S Utture, A Thavamanni, K Prabhash, A Dutt.   

Abstract

BACKGROUND: The Medical Oncology Department at Tata Memorial Hospital, the single largest tertiary cancer care center in Asia, receives in-house registered and referral patient samples from all parts of the country. Our recent studies establish 23% EGFR mutation frequency among Indian population. Here, we extend our study and report further analysis of distribution of different types of EGFR mutations in 1018 non small cell lung cancer patient, and its co-relation with clinical parameters and geographical variations across the country.
MATERIAL AND METHODS: This study is a retrospective analysis on all the patients who were referred for EFGR testing as a routine service over a 1.5 year period. This was part of standard care. EGFR kinase domain mutations in exon 18-21 were probed by TaqMan probe-based assays in 1018 NSCLC patients. RESULTS AND DISCUSSION: While EGFR exon 19 mutations, the most frequent EGFR mutation, were found be higher among non smokers females, we find surprisingly higher incidence of exon 21 mutations among EGFR mutation positive male smokers of Indian ethnicity. Furthermore, as Indian population is known to be composed of a gradient admixture of Ancestral North Indian (with genetic influence from Middle Easterners, Central Asians, and Europeans harboring variant EGFR mutation frequency) and Ancestral South Indians, as a paradox our study indicates comparable EGFR mutation frequency across different geographical locations within India
CONCLUSION: Geographically there is uniform distribution in the EGFR mutation frequency within India. Further more, while exon 19 mutations are predominant among non smokers, higher incidence of exon 21 mutations exists among EGFR mutation positive male smokers of Indian ethnicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979200      PMCID: PMC5808828          DOI: 10.4103/0019-509X.117023

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  25 in total

1.  Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authors:  David M Jackman; Beow Y Yeap; Lecia V Sequist; Neal Lindeman; Alison J Holmes; Victoria A Joshi; Daphne W Bell; Mark S Huberman; Balazs Halmos; Michael S Rabin; Daniel A Haber; Thomas J Lynch; Matthew Meyerson; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

Review 2.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

Authors:  Hiroyuki Yasuda; Susumu Kobayashi; Daniel B Costa
Journal:  Lancet Oncol       Date:  2011-07-19       Impact factor: 41.316

3.  Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

Authors:  Takayuki Kosaka; Yasushi Yatabe; Hideki Endoh; Hiroyuki Kuwano; Takashi Takahashi; Tetsuya Mitsudomi
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

4.  The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China.

Authors:  M Li; Q Zhang; L Liu; Z Liu; L Zhou; Z Wang; S Yue; H Xiong; L Feng; S Lu
Journal:  Neoplasma       Date:  2011       Impact factor: 2.575

5.  [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].

Authors:  Meng-hong Sun; Fei Yang; Lei Shen; Ling Zhang; Ying Chen; Xu Cai; Xiao-li Zhu; Xiao-yan Zhou
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  2011-10

6.  Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience.

Authors:  V Noronha; R Dikshit; N Raut; A Joshi; C S Pramesh; K George; J P Agarwal; A Munshi; K Prabhash
Journal:  Indian J Cancer       Date:  2012 Jan-Mar       Impact factor: 1.224

7.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

Authors:  Maria E Arcila; Khedoudja Nafa; Jamie E Chaft; Natasha Rekhtman; Christopher Lau; Boris A Reva; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Mol Cancer Ther       Date:  2013-01-31       Impact factor: 6.261

Review 9.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.

Authors:  A F Gazdar
Journal:  Oncogene       Date:  2009-08       Impact factor: 9.867

10.  Reconstructing Indian population history.

Authors:  David Reich; Kumarasamy Thangaraj; Nick Patterson; Alkes L Price; Lalji Singh
Journal:  Nature       Date:  2009-09-24       Impact factor: 49.962

View more
  11 in total

1.  Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.

Authors:  Bibhu Ranjan Das; Sangeet Bhaumik; Firoz Ahmad; Aziz Mandsaurwala; Heena Satam
Journal:  Pathol Oncol Res       Date:  2015-01-31       Impact factor: 3.201

2.  Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.

Authors:  Deepali Jain; Sobuhi Iqbal; Ritika Walia; Prabhat Malik; Sunu Cyriac; Sandeep R Mathur; Mehar C Sharma; Karan Madan; Anant Mohan; Ashu Bhalla; Sushmita Pathy; Lalit Kumar; Randeep Guleria
Journal:  Indian J Med Res       Date:  2016-03       Impact factor: 2.375

3.  Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy.

Authors:  Stalin Bala; Sadashivudu Gundeti; Vijay Gandhi Linga; Lakshmi Srinivas Maddali; Raghunadha Rao Digumarti; Shantveer G Uppin
Journal:  Indian J Med Paediatr Oncol       Date:  2016 Oct-Dec

4.  Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey.

Authors:  Kumar Prabhash; Purvish M Parikh; Senthil J Rajappa; Vanita Noronha; Amit Joshi; Shyam Aggarwal; Shailesh Bondarde; Shekar Patil; Chirag Desai; Palanki Satya Dattatreya; Rajesh Naik; Sohit Anand; Raju Titus Chacko; Ghanshyam Biswas; Tarini P Sahoo; Deepak Dabkara; Vijay Patil; M V Chandrakant; Pratap K Das; Ashok K Vaid; Dinesh C Doval
Journal:  South Asian J Cancer       Date:  2018 Jul-Sep

5.  Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association.

Authors:  Anurag Mehta; Nayana N Sriramanakoppa; Poojan Agarwal; Gayatri Viswakarma; Smreti Vasudevan; Manoj Panigrahi; Dushyant Kumar; Mumtaz Saifi; Irfan Chowdhary; D C Doval; Moushumi Suryavanshi
Journal:  South Asian J Cancer       Date:  2019 Oct-Dec

6.  Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients.

Authors:  Rajesh Kota; Sadashivudu Gundeti; Muralidhar Gullipalli; Vijay Gandhi Linga; Lakshmi Srinivas Maddali; Raghunadharao Digumarti
Journal:  Lung India       Date:  2015 Nov-Dec

7.  Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival.

Authors:  Venkata Nagarjuna Maturu; Navneet Singh; Amanjit Bal; Nalini Gupta; Ashim Das; Digambar Behera
Journal:  Lung India       Date:  2016 May-Jun

8.  Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer.

Authors:  Vidya H Veldore; Anuradha Choughule; Tejaswi Routhu; Nitin Mandloi; Vanita Noronha; Amit Joshi; Amit Dutt; Ravi Gupta; Ramprasad Vedam; Kumar Prabhash
Journal:  Lung Cancer (Auckl)       Date:  2018-01-03

9.  Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma.

Authors:  Saniya Sharma; Nalini Gupta; Navneet Singh; Rini Chaturvedi; Digambar Behera; Arvind Rajwanshi
Journal:  Cytojournal       Date:  2018-04-02       Impact factor: 2.091

Review 10.  Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.

Authors:  Elisabeth Smolle; Katharina Leithner; Horst Olschewski
Journal:  Thorac Cancer       Date:  2019-12-04       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.